NanoViricides, Inc. (NNVC)

US — Healthcare Sector
Peers: RNXT  AXLA  ADIL  BTTX  KTTA  ZIVO  QNRX  ABIO  ABVC  INDP  FBRX  RZLT  TPST  CMRA  THRX  ERAS  AMTI 

Automate Your Wheel Strategy on NNVC

With Tiblio's Option Bot, you can configure your own wheel strategy including NNVC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NNVC
  • Rev/Share 0.0
  • Book/Share 0.5512
  • PB 2.7578
  • Debt/Equity 0.0
  • CurrentRatio 2.2748
  • ROIC -1.1171

 

  • MktCap 24429440.0
  • FreeCF/Share -0.5243
  • PFCF -2.9072
  • PE -2.5044
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.9538

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

NanoViricides president backs FDA's targeted COVID booster policy shift
NNVC
Published: May 22, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) president Dr Anil Diwan has welcomed a new US Food and Drug Administration policy that limits broad COVID-19 vaccine booster recommendations, calling it a “rational and scientific” shift that could help restore public trust in health institutions. The updated FDA guidance recommends COVID booster shots only for adults aged 65 and older, and for individuals aged six months and above with underlying conditions that put them at risk of severe disease.

Read More
image for news NanoViricides president backs FDA's targeted COVID booster policy shift
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NNVC
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.

Read More
image for news The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox
NNVC
Published: May 16, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections in Central Africa, marking a major step in the company's broader strategy to address a growing range of viral public health threats with no currently approved treatments. The Connecticut-based biotech firm recently received clearance from the Democratic Republic of Congo's National Ethics Committee to proceed with the submission following a review of Phase I safety data and promising results from preclinical Mpox studies in lethal animal models.

Read More
image for news NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
NNVC
Published: May 14, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid rising concern over vaccine failure and the lack of effective treatments. The Shelton, Connecticut-based company said it has initiated animal efficacy studies to evaluate NV-387 as a treatment for measles, noting there are currently no approved antiviral drugs for the disease.

Read More
image for news NanoViricides progresses antiviral portfolio as measles and MPox threats rise
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
NNVC
Published: May 08, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug NV-387 for treating Mpox, a step toward regulatory submission in a region where the disease continues to spread. The approval, granted by the National Ethics Committee for Health (CNES) under the DRC's Ministry of Public Health, clears the company to submit a full clinical trial application (CTA) for NV-387, NanoViricides said.

Read More
image for news NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
NanoViricides advances measles drug development amid rising US cases
NNVC
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. The Shelton, Connecticut-based biotechnology firm said it has completed propagation of the measles virus in its biosafety level-2 virology lab and is preparing to conduct an animal model study to test its clinical-stage antiviral candidate NV-387.

Read More
image for news NanoViricides advances measles drug development amid rising US cases
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NNVC
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral

SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides further details on its Measles drug development program herewith.

Read More
image for news Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
NNVC
Published: March 28, 2025 by: Proactive Investors
Sentiment: Positive

The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week. The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.

Read More
image for news NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold
NNVC, NWVCF, TRRXF
Published: February 21, 2025 by: Proactive Investors
Sentiment: Neutral

Read More
image for news Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NNVC
Published: February 19, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.

Read More
image for news NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
NNVC
Published: February 11, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.

Read More
image for news NanoViricides announces readiness to combat bird flu with antiviral drug NV-387

About NanoViricides, Inc. (NNVC)

  • IPO Date 2005-10-26
  • Website https://www.nanoviricides.com
  • Industry Biotechnology
  • CEO Dr. Anil R. Diwan Ph.D.
  • Employees 7

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.